Showing papers by "Transgene SA published in 2012"
TL;DR: TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2 that is focused on advanced non-small cell lung cancer in combination with first line chemotherapy.
Abstract: TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.
36 citations
Patent•
19 Oct 2012TL;DR: In this paper, an antibody able to bind to CSF-IR for modulating macrophage activation was used to promote Ml-type (macrophage M1 polarization) immune response.
Abstract: The invention is generally directed to promoting Ml-type (macrophage M1 polarization) immune response by administering a compound that modulates macrophage activation. The invention is directed to the use of an antibody able to bind to CSF-IR for modulating macrophage activation. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-IR in a patient by assessing the in vivo or in vitro activation of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-IR on a subject being treated.
20 citations
TL;DR: Examining the ability of recombinant modified vaccinia virus Ankara (rMVA) vector to induce an immune response against a well-tolerated self-antigen found the AFP transmembrane form is more immunogenic.
Abstract: Aim. To investigate the ability of recombinant modified vaccinia virus Ankara (rMVA) vector to induce an immune response against a well-tolerated self-antigen. Methods. rMVA vectors expressing different form of α-fetoprotein (AFP) were produced and characterized. Naive mice were vaccinated with MVA vectors expressing the AFP antigen in either a secreted, or a membrane-bound, or an intracellular form. The immune response was monitored by an IFNΓ ELISpot assay and antibody detection. Results. Vaccination with the membrane-associated form of AFP induced a stronger CD8+ T-cell response compared to the ones obtained with the MVA encoding the secreted or the intracellular forms of AFP. Moreover, the vaccination with the membrane-bound AFP elicited the production of AFP-specific antibodies. Conclusions. The AFP transmembrane form is more immunogenic. Expressing a membrane-bound form in the context of an MVA vaccination could enhance the immunogenicity of a self-antigen.
6 citations
Patent•
19 Oct 2012TL;DR: In this paper, an antibody able to bind to CSF-IR for modulating macrophage activation was used to promote M1-type (macrophage M1 polarization) immune response.
Abstract: The invention is generally directed to promoting M1-type (macrophage M1 polarization) immune response by administering a compound that modulates macrophage activation. The invention is directed to the use of an antibody able to bind to CSF-IR for modulating macrophage activation. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-IR in a patient by assessing the in vivo or in vitro activation of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-IR on a subject being treated.
2 citations